Methazolamide

Methazolamide
Ball-and-stick model of the methazolamide molecule
Clinical data
Other namesN-(3-Methyl-5-sulfamoyl-3H-1,3,4-thiadiazol-2-ylidene) ethanamide
AHFS/Drugs.comMonograph
MedlinePlusa601233
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding~55%
Elimination half-life~14 hours
Identifiers
  • N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.008.243 Edit this at Wikidata
Chemical and physical data
FormulaC5H8N4O3S2
Molar mass236.26 g·mol−1
3D model (JSmol)
  • O=S(=O)(C\1=N\N(C(=N/C(=O)C)/S/1)C)N
  • InChI=1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)/b7-4- checkY
  • Key:FLOSMHQXBMRNHR-DAXSKMNVSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Methazolamide (trade name Neptazane) is a potent carbonic anhydrase inhibitor. It is indicated in the treatment of increased intraocular pressure (IOP) in chronic open-angle glaucoma and secondary glaucoma. Also it is used preoperatively in acute angle-closure (narrow-angle) glaucoma where lowering the IOP is desired before surgery.

This drug has displayed teratogenic effects in rats. Compared to another drug in the same class, acetazolamide, methazolamide requires a lower dose when administered to patients.

Recently, research has also uncovered a potential new role for this drug, addressing tau toxicity, a theorized cause for diseases such as Alzheimer’s. [1]

References

[edit]
  1. ^ Lopez A, Siddiqi FH, Villeneuve J, Ureshino RP, Jeon HY, Koulousakis P, et al. (October 2024). "Carbonic anhydrase inhibition ameliorates tau toxicity via enhanced tau secretion". Nature Chemical Biology. 21 (4): 577–587. doi:10.1038/s41589-024-01762-7. PMC 11949835. PMID 39482469.

Further reading

[edit]